Trump Administration Plans Medicare/Medicaid Coverage for Weight Loss Drugs
Trump Administration considers Covering Weight-Loss Drugs for Medicaid and medicare
The potential move coudl substantially expand access to GLP-1 medications, but raises questions about long-term affordability.
The Trump administration is reportedly considering a policy shift that would allow state Medicaid programs and Medicare Part D insurance plans to voluntarily cover GLP-1 drugs, a class of medications that includes popular weight-loss treatments like Ozempic and Wegovy. This potential change,if enacted,would represent a significant departure from the administration’s earlier stance that these programs would not cover weight-loss drugs.
A New Era for Weight-Loss Medication Coverage?
GLP-1 drugs, known for their effectiveness in managing type 2 diabetes and promoting weight loss, typically come with a hefty price tag, frequently enough ranging from $5,000 to $7,000 per year. Currently, insurance coverage for these medications is generally approved only when patients have co-existing conditions frequently enough linked to obesity, such as diabetes, heart disease, and cancer.
The proposed plan, slated to begin implementation in April 2026 for Medicaid and january 2027 for Medicare, could dramatically increase the number of Americans with access to these transformative treatments. This initiative is particularly noteworthy given the burgeoning weight-loss drug market, which some analysts predict could generate over $150 billion in revenue by the next decade. Shares of Eli Lilly, a key player in this market, saw a nearly 2% increase in premarket trading on Friday following the news.
Navigating the Cost and Policy Landscape
While the prospect of wider coverage is exciting, the high cost of GLP-1 drugs has sparked considerable debate about their long-term affordability for the public purse. the Centers for Medicare & Medicaid Services (CMS), Eli Lilly, and Novo Nordisk did not immediately respond to requests for comment on the reported plan.
This potential policy shift could also highlight internal divisions within the administration. CMS head Mehmet Oz has previously expressed praise for these types of drugs,while health Secretary Robert F. kennedy Jr. has voiced concerns about their high cost and whether they serve as a true substitute for a healthy lifestyle. The decision to move forward with covering these medications would mark a notable pivot in federal health policy, potentially reshaping how weight management is approached within the nation’s largest public health insurance programs.